Clinical trial
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By…
NCT00121186 · SWOG Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00121186 |
|---|---|
| Title | S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma |
| Official title | Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | fludarabine phosphate, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation |
| Enrollment | 1 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Dec 1, 2011 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 3, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: